Tag Archive for: Immunotherapy

Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In In Vivo Cell Reprogramming To Treat Cancer

Financing to advance first platform designed to reprogram cancer cells into immune cells as pan-tumoral cancer treatment Novo Holdings participation follows earlier investment and incubation through seed phase Financing co-led by RV Invest and Johnson & Johnson Innovation, joined by existing investors Boehringer Ingelheim Venture Fund and Industrifonden COPENHAGEN – March 14th, 2024 – Novo Holdings, […]

Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology

Co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc. with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden Lead program is AT-108, a first-in-class, off-the-shelf intra-tumoral therapy that leads to personalized and potent anti-cancer immune responses Expanding R&D team to further develop AT-108 and broaden in vivo reprogramming […]

HERVOLUTION Therapeutics Appoints Biotech Builder J. Robert Coleman as CEO to Accelerate Groundbreaking Immunotherapies to Treat Dark Genome Targets in Cancer, Aging, and Neurodegeneration

Copenhagen, Denmark & New York, USA — 19 Dec 2023— HERVOLUTION Therapeutics ApS (‘HERVOLUTION’), a pioneering biotechnology company focused on developing novel immunotherapies to treat dark genome targets in cancer, aging, and neurodegeneration, today announces the appointment of J. Robert Coleman, PhD, MBA as its Chief Executive Officer. Robert Coleman PhD, MBA, has over 12 […]

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Trial expected to reach the primary endpoint of progression free survival in the second half of 2025 Per-protocol interim analysis expected in mid-2024 NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, announced today that it has completed enrollment in the pivotal […]

Lytix Biopharma presents third quarter 2023 results

Oslo, 09 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today releases its third quarter 2023 results. Dr. Øystein Rekdal, Chief Executive Officer of Lytix Biopharma, commented: “We continue our efforts to demonstrate the clinical benefits of LTX-315 in patients with skin cancers. First and foremost, we are […]